UNSPSC 51292301: Mosapramine

This classification denotes an antidepressant agent with the molecular formula C28H35ClN4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04UZQ7O9SJ, chemically known as (- )-1-(3-(3-chloro-10,11-dihydro-5h-dibenz(b,f)azepin-5-yl)propyl)hexahydrospiro(imidazo(1,2-a)pyridine-3(2h),4-piperidin)-2-one. but generally known as mosapramine, which bears US NIH Compound Identifier 4257. European Medicines Agency schedules Mosapramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09073MIG.

UNSPSC 51292301 Mosapramine, a Commodity code, nominally addresses a specific pharmaceutical product, but recent state and local solicitations tagged under this code do not align with that narrow scope. Instead, they reflect procurement of broader pharmaceutical and drug-related products and services — naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products. State and local issuing bodies pursuing these opportunities include county health departments (Seminole County, Florida), state HHS commissions and healthcare agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing organizations administering programs on behalf of member states and localities (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and participating jurisdictions). The work being solicited spans both product supply — unit-based procurement of naloxone and drug deactivation systems with quarterly delivery schedules — and program-level contracting to establish standing contracts for pharmaceutical distribution through authorized wholesale channels to multiple government facilities.

Recent activity clusters in Florida, Texas, and Minnesota. Seminole County posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: posted date and response deadline do not align in the source). The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a statewide Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, an exploratory solicitation with no formal award timeline. The Minnesota Department of Administration, through MMCAP, released RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to be supplied through authorized wholesalers, with proposals due March 26, 2026 and awarded contracts effective July 1, 2026; this vehicle serves multiple states and local government facilities. The code shows misalignment between its nominal pharmaceutical product focus and the actual procurement activity it captures in state and local government right now, which emphasizes harm-reduction and program-level pharmaceutical contracting rather than a single active pharmaceutical ingredient.